Given its ever-growing role as a critical region for the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.

After a searing advisory committee on aducanumab, FDA reviewers undertook an extensive effort to counter or discount the panel’s criticisms, newly released review documents show. Among the unusual moves by the agency was the citation of data from two investigational products, Lilly’s donanemab and Biogen/Eisai’s BAN2401, as evidence in support of aducanumab.

In this audio interview, Organon’s head for the Asia Pacific region talks to Scrip on the company’s ambitions in the women’s health segment and the outlook for its biosimilars and established brands portfolios.

In this week's podcast edition of Five Must-Know Things: a pioneering KRAS inhibitor approval; Organon’s CEO on the company’s plans; Astellas’s mid-term ambitions; trial disappointment for Novartis’s Beovu; and Indian plans for a pediatric COVID vaccine.